Literature DB >> 937754

Cardiovascular and respiratory changes in response to change of posture in the very obese.

D R Paul, J L Hoyt, A R Boutros.   

Abstract

Circulatory and respiratory effects of change of posture from sitting to supine were studied in 11 obese patients scheduled for gastric bypass operations. Patients were studied on the morning of operation before any medication was given. Average weight was 138.8 kg, 108.6 per cent above ideal weight. Change of posture from sitting to supine was associated with 11 per cent increase in oxygen consumption (VO2), 35.5 per cent increase in cardiac output (CO), 35.8 per cent increase in cardiac index, 17.85 per cent decrease in arteriovenous oxygen difference, 31 per cent increase in mean pulmonary arterial pressure, 44 per cent increase in pulmonary-artery wedge pressure, 21.5 per cent decrease in peripheral resistance (PR), 6 per cent decrease in heart rate, and 17.7 per cent increase in venous admixture (QS/Qt). All these changes were significant. There was no change in mean arterial pressure, alveolo-arterial O2 difference and respiratory rate. The increase in CO was attributed to reduction in PR and to increased V02 probably due to increased work of breathing.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 937754     DOI: 10.1097/00000542-197607000-00013

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  3 in total

Review 1.  Controversies in perioperative anesthetic management of the morbidly obese: I am a surgeon, why should I care?

Authors:  Ashish C Sinha; Preet Mohinder Singh
Journal:  Obes Surg       Date:  2015-05       Impact factor: 4.129

2.  Anaesthetic waste gas scavenging systems.

Authors:  R J Armstrong; E J Kershaw; S P Bourne; L Strunin
Journal:  Br Med J       Date:  1977-04-09

3.  Gastroplasty for respiratory insufficiency of obesity.

Authors:  H J Sugerman; R P Fairman; A K Lindeman; J A Mathers; L J Greenfield
Journal:  Ann Surg       Date:  1981-06       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.